Krebs Von Den Lungen-6 as a biomarker for lung disease activity and diagnosis in systemic juvenile idiopathic arthritis

Clicks: 5
ID: 338672
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #62 of 64 articles by views in international journal of rheumatology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: Children with systemic juvenile idiopathic arthritis (sJIA) and lung disease (LD) are at increased risk of serious complications and premature mortality, making early detection and intervention critical. Krebs von den Lungen 6 (KL-6) is a blood-based biomarker for interstitial lung disease in adults; however, its role in pediatric LD is unclear. This study evaluates KL-6 as a discriminatory and disease activity biomarker for sJIA-LD. METHODS: Thirty-two patients with sJIA-LD were enrolled through the Childhood Arthritis and Research Alliance (CARRA) Registry. Comparators included sJIA patients without LD, children with primary pulmonary alveolar proteinosis (PAP), and healthy control children. RESULTS: Median KL-6 levels were significantly higher in sJIA-LD (596.3 U/mL [IQR 273.5-5,896.3]) compared to sJIA without LD (193.0 U/mL [151.0-252.0], p < 0.0001) and healthy controls (171.9 U/mL [89.7-224.3], p = 0.001), with no difference versus PAP (596.3 vs. 1429.9, p = 0.30). A cut-off of 259.5 U/mL yielded 81.3% sensitivity and 80.9% specificity for LD (AUC 0.856, p < 0.0001). At 371.5 U/mL, specificity reached 100% with 68.7% sensitivity and 100% positive predictive value. SJIA-LD features associated with higher median KL-6 levels included oxygen requirement, abnormal pulse oximeter (<90%), and abnormal chest radiographs. KL-6 strongly correlated with physician global assessment of lung disease but not with markers of systemic inflammation or macrophage activation syndrome. CONCLUSION: KL-6 is a useful biomarker for discriminating LD and evaluating disease activity in sJIA-LD. Future efforts should focus on the utility of KL-6 for monitoring disease progression, treatment response, and predicting long-term disease trajectories.
Reference Key
openalex_W7225250623 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Eileen C. Rife, Alexi Auld, Guihua Zhai, Esraa M. Eloseily, Yukiko Kimura, Michael G. Matt, Christopher T. Towe, Grant S. Schulert, for the CARRA Registry FROST Investigators and the CARRA Registry sJIA-LD Cohort Investigators, S Ardoin, K Baszis, H Brunner, J Chang, D Co, A Cooper, C Correll, M DeGuzman, K Ede, S Hong, J Hsu, C Inman, S Kim, M Klein-Gitelman, M Mannion, K Moore, K Nanda, M Rosenkranz, D Wahezi, J Weiss, P Weiss, L Woolnough
Journal international journal of rheumatology
Year 2026
DOI
10.1093/rheumatology/keag613
URL
https://doi.org/10.1093/rheumatology/keag613
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.